(Q36631503)

15 August 2017

1 reference

title

Probiotics: do they help to control intestinal inflammation? (English)

1 reference

15 August 2017

0 references

Böhm SK

1

1 reference

15 August 2017

Kruis W

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Annals of the New York Academy of Sciences

15 August 2017

published in

1 reference

15 August 2017

volume

1072

1 reference

15 August 2017

page(s)

339-350

1 reference

Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Dysbiosis in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Probiotics in inflammatory bowel disease: is it all gut flora modulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

PROBIOTICS: GROWTH-PROMOTING FACTORS PRODUCED BY MICROORGANISMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Host-flora interactions in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Microbial-gut interactions in health and disease. Probiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Host-bacterial mutualism in the human intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Probiotics used in human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

[Methodological basis for the development of consensus recommendations]

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

A pilot trial of Saccharomyces boulardii in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Treatment of ulcerative colitis using fecal bacteriotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Factors associated with ileal mucosal morphology and inflammation in patients with ileal pouch-anal anastomosis for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Assessment of Mucosal Inflammation and Circulation in Response to Probiotics in Patients Operated with Ileal Pouch Anal Anastomosis for Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Saccharomyces boulardii in maintenance treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Lactobacillus GG in inducing and maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.005

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1326.005

1 reference

15 August 2017

1 reference